Eurofarma strengthens presence in Argentina with acquisition of Buxton
Published in: September 12, 2019
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, September 2019 – Eurofarma, a company with Brazilian capital among the leading pharmaceutical companies in Latin America, once again strengthens its operations in Argentina with the acquisition of Laboratorio Buxton.
The transaction reaffirms the company’s commitment to continue focusing on growth of the country’s operations and will foster operations in new therapeutic classes and segments, such as fertility, with the marketing of biological products.
With the acquisition, Eurofarma and Buxton join forces for a portfolio of over 60 products. Growth of the newly acquired line is expected to surpass 40% in 2020. There is also potential to extend Buxton licenses to other Latin American countries where Eurofarma operates.
The pharmacy channel in Argentina had audited sales of USD 5.6 billion in 2018 and the country accounts for 14% of Latin American sales, standing out as a key market within the region.
In addition to the recent acquisition of Buxton, Eurofarma – which has been present in Argentina for 10 years – entered the country with the acquisition of a small laboratory, then later acquired an important production plant in the country, as well as OTC products under a brand name widely recognized in the market. The initiatives are in line with the challenge of consolidating the company’s Latin American operations and growing inorganically in the region. The goal highlighted in Eurofarma’s Vision 2022 establishes that international operations will represent 30% of the company’s total sales on this horizon. In addition to Argentina, Eurofarma has own operations in 19 other countries throughout the region.
About Eurofarma Group
Eurofarma is a health company focused on offering products and services to improve people’s lives with quality, innovation and fair prices across all major pharmaceutical segments: Prescription, Generic, Hospital, Oncology, and Nonprescription Drugs, as well as Veterinary Medicine. In Brazil alone, the company offers 287 different molecules and over 600 products. Eurofarma is a leader in medical prescriptions, serving 30 different specialties and covering 101 therapeutic classes, which account for 89% of retail pharmaceutical sales. The company has the largest sales force in the country, which visits approximately 600,000 doctors monthly.
Founded in 1972 and the first pharmaceutical multinational with 100% Brazilian capital, it has own operations in 20 countries and maintains a major manufacturing park in Brazil, as well as plants in 6 other Latin American countries. The group reported sales of BRL 4.3 billion in 2018 and employs over 6,700 employees.
Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br
Press Information
G&A – Public Relations
André Pascowitch – +55 (11) 5090-8646 – andre@gaspar.com.br
Guilherme Gaspar – +55 (11) 3065-3045 – guilherme@gaspar.com.br
The transaction reaffirms the company’s commitment to continue focusing on growth of the country’s operations and will foster operations in new therapeutic classes and segments, such as fertility, with the marketing of biological products.
With the acquisition, Eurofarma and Buxton join forces for a portfolio of over 60 products. Growth of the newly acquired line is expected to surpass 40% in 2020. There is also potential to extend Buxton licenses to other Latin American countries where Eurofarma operates.
The pharmacy channel in Argentina had audited sales of USD 5.6 billion in 2018 and the country accounts for 14% of Latin American sales, standing out as a key market within the region.
In addition to the recent acquisition of Buxton, Eurofarma – which has been present in Argentina for 10 years – entered the country with the acquisition of a small laboratory, then later acquired an important production plant in the country, as well as OTC products under a brand name widely recognized in the market. The initiatives are in line with the challenge of consolidating the company’s Latin American operations and growing inorganically in the region. The goal highlighted in Eurofarma’s Vision 2022 establishes that international operations will represent 30% of the company’s total sales on this horizon. In addition to Argentina, Eurofarma has own operations in 19 other countries throughout the region.
About Eurofarma Group
Eurofarma is a health company focused on offering products and services to improve people’s lives with quality, innovation and fair prices across all major pharmaceutical segments: Prescription, Generic, Hospital, Oncology, and Nonprescription Drugs, as well as Veterinary Medicine. In Brazil alone, the company offers 287 different molecules and over 600 products. Eurofarma is a leader in medical prescriptions, serving 30 different specialties and covering 101 therapeutic classes, which account for 89% of retail pharmaceutical sales. The company has the largest sales force in the country, which visits approximately 600,000 doctors monthly.
Founded in 1972 and the first pharmaceutical multinational with 100% Brazilian capital, it has own operations in 20 countries and maintains a major manufacturing park in Brazil, as well as plants in 6 other Latin American countries. The group reported sales of BRL 4.3 billion in 2018 and employs over 6,700 employees.
Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br
Press Information
G&A – Public Relations
André Pascowitch – +55 (11) 5090-8646 – andre@gaspar.com.br
Guilherme Gaspar – +55 (11) 3065-3045 – guilherme@gaspar.com.br